Ask AI
ProCE Banner Activity

Defining  Our Treatment Goals: Raising the Bar in PBC Management Podcast

Podcast Episodes

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn from Dr Aliya F. Gulamhusein, Dr Christopher L. Bowlus, and Dr Aparna Goel, how these developments are helping to redefine and elevate PBC treatment goals. This episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care.

Released: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, physician associates, nurse practitioners, and other HCPs involved in the care of patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop treatment goals for PBC that include evidence-based biochemical targets and improvement in symptoms and quality of life

  • Design comprehensive treatment plans for patients with PBC

Disclosure

Primary Author

Christopher L. Bowlus, MD: researcher (paid to institution): Calliditas, ChemoMab, COUR, Cymabay, Gilead, GSK, Hanmi, Ipsen, Mirum, Novartis, Pliant, Zydus; consultant/advisor/speaker: Alnylam, Amgen, AstraZeneca, ChemoMab, Esperion, Gilead, GSK, Ipsen, Kezar, Mirum, Pliant, Takeda.

Aparna Goel, MD: consultant/advisor/speaker/researcher: Gilead, Ipsen, Mirum.

Aliya F. Gulamhusein, MD, MPH, FRCPC: consultant/advisor/speaker: Advanz, Gilead, Ipsen, Mirum.